CYP19 Genetic Polymorphism Haplotype AASA Is Associated with a Poor Prognosis in Premenopausal Women with Lymph Node-Negative, Hormone Receptor-Positive Breast Cancer

Table 3

Overall survival, disease-free survival, and distant disease-free survival of LN-negative, HR-positive breast cancer patients with the CYP19 AASA haplotype.

Haplotype Subject; number = 214; Allele number = 428; (allelic frequency)	OS			DFS			DDFS
	Event number; (frequency)	Hazard ratio (95% CI); aHR (95% CI)	𝑃	Event number; (frequency)	Hazard ratio (95% CI); aHR (95% CI)	𝑃	Event number; (frequency)	Hazard ratio (95% CI); aHR (95% CI)	𝑃
AASA versus non-AASA (17.1% versus 82.9%)
Total	27 (10.3 %)	1.9 (1.1–3.5); 2.1 (1.2–3.9)	0.03; 0.01	51 (23.8%)	1.9 (1.2–3.0); 2.0 (1.3–3.2)	0.004; 0.002	41 (19.2%)	1.8 (1.1–3.0); 2.0 (1.2–3.2)	0.02; 0.008
Premenopausal		2.9 (1.5–5.7); 3.3 (1.6–6.8)	0.002; 0.001		2.4 (1.4–3.9); 2.5 (1.5–4.2)	0.001; 0.0008		2.6 (1.5–4.6); 2.9 (1.6–5.3)	0.0009; 0.0004
Postmenopausal		0.6 (0.1–2.7); 0.7 (0.2–3.4)	0.53; 0.71		1.2 (0.5–2.9); 1.4 (0.6–3.6)	0.72; 0.44		0.8 (0.3–2.2); 0.9 (0.3–2.6)	0.60; 0.81
AASC versus non-AASC (8.9% versus 91.1%)
Total	27 (10.3 %)	2.0 (0.9–4.2); 2.9 (1.3–6.3)	0.08; 0.008	51 (23.8%)	1.3 (0.7–2.5); 1.5 (0.8–2.9)	0.36; 0.22	41 (19.2%)	1.3 (0.6–2.5); 1.6 (0.8–3.4)	0.51; 0.18
Premenopausal		1.5 (0.5–4.1); 2.1 (0.7–6.4)	0.48; 0.18		1.0 (0.4–2.4); 1.1 (0.4–2.7)	0.93; 0.86		1.1 (0.4–2.7); 1.4 (0.5–3.6)	0.89; 0.54
Postmenopausal		3.3 (1.1–10.0); 4.4 (1.4–14.1)	0.04; 0.01		2.2 (0.8–5.6); 3.1 (1.1–8.3)	0.11; 0.03		1.7 (0.6–5.0); 2.5 (0.8–7.6)	0.31; 0.10
CASA versus non-CASA (11.9% versus 88.1%)
Total		0.6 (0.2–1.6); 0.6 (0.2–1.6)	0.30; 0.31		0.8 (0.4–1.5); 0.8 (0.4–1.6)	0.48; 0.58		0.8 (0.4–1.7); 0.8 (0.4–1.7)	0.62; 0.58
Premenopausal		0.6 (0.2–2.1); 0.6 (0.2–2.1)	0.45; 0.45		0.8 (0.3–1.7); 0.8 (0.4–1.8)	0.49; 0.60		0.7 (0.3–1.8); 0.7 (0.3–1.7)	0.70; 0.40
Postmenopausal		0.5 (0.1–3.5); 0.5 (0.1–4.1)	0.45; 0.53		0.8 (0.3–2.7); 0.8 (0.2–2.7)	0.75; 0.69		1.1 (0.3–3.8); 1.1 (0.3–4.2)	0.83; 0.85
CCLA versus non-CCLA (41.1% versus 58.9%)
Total		0.6 (0.3–1.1); 0.6 (0.3–1.0)	0.07; 0.06		0.8 (0.5–1.2); 0.8 (0.5–1.2)	0.28; 0.22		0.8 (0.5–1.3); 0.8 (0.5–1.2)	0.33; 0.27
Premenopausal		0.5 (0.3–1.1); 0.6 (0.3–1.2)	0.10; 0.14		0.7 (0.4–1.2); 0.8 (0.5–1.3)	0.22; 0.30		0.7 (0.4–1.2); 0.7 (0.4–1.3)	0.20; 0.28
Postmenopausal		0.7 (0.3–1.9); 0.6 (0.2–1.6)	0.46; 0.33		0.9 (0.5–1.9); 0.8 (0.4–1.6)	0.88; 0.49		1.0 (0.5–2.2); 0.8 (0.4–1.8)	0.91; 0.64
CCLC versus non-CCLC (8.9% versus 91.1%)
Total		0.8 (0.3–2.1); 0.6 (0.2–1.6)	0.62; 0.28		0.6 (0.2–1.3); 0.4 (0.2–1.0)	0.18; 0.05		0.5 (0.2–1.3); 0.4 (0.1–1.0)	0.14; 0.05
Premenopausal		0.6 (0.1–2.3); 0.3 (0.1–1.5)	0.42; 0.16		0.5 (0.2–1.5); 0.4 (0.1–1.2)	0.22; 0.10		0.3 (0.1–1.4); 0.3 (0.1–1.1)	0.14; 0.07
Postmenopausal		1.2 (0.3–5.4); 1.0 (0.2–4.5)	0.78; 0.99		0.7 (0.2–2.7); 0.5 (0.1–2.4)	0.56; 0.42		0.7 (0.2–3.1); 0.7 (0.2–2.9)	0.67; 0.60
CCSA versus non-CCSA (7.5% versus 92.5%)
Total		1.9 (0.9–4.2); 1.8 (0.8–4.0)	0.11; 0.15		1.1 (0.5–2.2); 1.1 (0.5–2.4)	0.85; 0.72		1.4 (0.7–2.9); 1.4 (0.7–3.0)	0.35; 0.35
Premenopausal		1.8 (0.6–5.1); 1.6 (0.6–4.8)	0.27; 0.37		1.1 (0.4–2.8); 1.0 (0.4–2.5)	0.81; 0.99		1.4 (0.6–3.6); 1.3 (0.5–3.3)	0.44; 0.63
Postmenopausal		2.1 (0.6–7.3); 1.8 (0.5–6.3)	0.23; 0.36		1.1 (0.3–3.5); 1.1 (0.3–3.8)	0.93; 0.85		1.4 (0.4–4.6); 1.4 (0.4–4.7)	0.59; 0.61